Lara Herrero

Dr. Lara Herrero

Institute for Glycomics, Griffith University, Southport, Qld, Australia
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
FBFelicity Burt
Felicity Burt
WCWeiqiang Chen
Weiqiang Chen
JMJonathan J Miner
Jonathan J Miner
DLDeborah J Lenschow
Deborah J Lenschow
AMAndres Merits
Andres Merits
SMSuresh Mahalingam
Suresh Mahalingam

1 October 2012 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
SMSuresh Mahalingam
Suresh Mahalingam
Lara HerreroLara Herrero
Lara Herrero
EPE Geoffrey Playford
E Geoffrey Playford
KSkirsten spann
kirsten spann
BHBelinda Herring
Belinda Herring
LWLin-Fa Wang
Lin-Fa Wang

11 April 2019 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
WLWai Suet Lee
Wai Suet Lee
JWJulie A. Webster
Julie A. Webster
EMEugene T. Madzokere
Eugene T. Madzokere
ESEloise B. Stephenson
Eloise B. Stephenson
Lara HerreroLara Herrero
Lara Herrero
Mosquito-borne diseases are associated with major global health burdens. Aedes spp. and Culex spp. are primarily responsible for the transmission of the most medically important mosquito-borne viruses, including dengue virus, West Nile virus and Zika virus. Despite the burden of these pathogens on human populations, the interactions between viruses and their mosquito hosts remain enigmatic. Viruses enter the midgut of a mosquito following the mosquito’s ingestion of a viremic blood meal. During infection, virus recognition by the mosquito host triggers their antiviral defense mechanism. Of these host defenses, activation of the RNAi pathway is the main antiviral mechanism, leading to the degradation of viral RNA, thereby inhibiting viral replication and promoting viral clearance. However, whilst antiviral host defense mechanisms limit viral replication, the mosquito immune system is unable to effectively clear the virus. As such, these viruses can establish persistent infection with little or no fitness cost to the mosquito vector, ensuring life-long transmission to humans. Understanding of the mosquito innate immune response enables the discovery of novel antivectorial strategies to block human transmission. This review provides an updated and concise summary of recent studies on mosquito antiviral immune responses, which is a key determinant for successful virus transmission. In addition, we will also discuss the factors that may contribute to persistent infection in mosquito hosts. Finally, we will discuss current mosquito transmission-blocking strategies that utilize genetically modified mosquitoes and Wolbachia-infected mosquitoes for resistance to pathogens.

1 January 2015 in Journal of Virology
Verified
Journal Article
Open access
PDF file
WCWeiqiang Chen
Weiqiang Chen
SFSuan-Sin Foo
Suan-Sin Foo
Adam TaylorAdam Taylor
Adam Taylor
ALAleksei Lulla
Aleksei Lulla
AMAndres Merits
Andres Merits
SMSuresh Mahalingam
Suresh Mahalingam
The recent global resurgence of arthritogenic alphaviruses, in particular chikungunya virus (CHIKV), highlights an urgent need for the development of therapeutic intervention strategies. While there has been significant progress in defining the pathophysiology of alphaviral disease, relatively little is known about the mechanisms involved in CHIKV-induced arthritis or potential therapeutic options to treat the severe arthritic symptoms associated with infection. Here, we used microcomputed tomographic (μCT) and histomorphometric analyses to provide previously undescribed evidence of reduced bone volume in the proximal tibial epiphysis of CHIKV-infected mice compared to the results for mock controls. This was associated with a significant increase in the receptor activator of nuclear factor-κB ligand/osteoprotegerin (RANKL/OPG) ratio in infected murine joints and in the serum of CHIKV patients. The expression levels of the monocyte chemoattractant proteins (MCPs), including MCP-1/CCL2, MCP-2/CCL8, and MCP-3/CCL7, were also highly elevated in joints of CHIKV-infected mice, accompanied by increased cellularity within the bone marrow in tibial epiphysis and ankle joints. Both this effect and CHIKV-induced bone loss were significantly reduced by treatment with the MCP inhibitor bindarit. Collectively, these findings demonstrate a unique role for MCPs in promoting CHIKV-induced osteoclastogenesis and bone loss during disease and suggest that inhibition of MCPs with bindarit may be an effective therapy for patients affected with alphavirus-induced bone loss.IMPORTANCEArthritogenic alphaviruses, including chikungunya virus (CHIKV) and Ross River virus (RRV), cause worldwide outbreaks of polyarthritis, which can persist in patients for months following infection. Previous studies have shown that host proinflammatory soluble factors are associated with CHIKV disease severity. Furthermore, it is established that chemokine (C-C motif) ligand 2 (CCL2/MCP-1) is important in cellular recruitment and inducing bone-resorbing osteoclast (OC) formation. Here, we show that CHIKV replicates in bone and triggers bone loss by increasing the RANKL/OPG ratio. CHIKV infection results in MCP-induced cellular infiltration in the inflamed joints, and bone loss can be ameliorated by treatment with an MCP-inhibiting drug, bindarit. Taken together, our data reveal a previously undescribed role for MCPs in CHIKV-induced bone loss: one of recruiting monocytes/OC precursors to joint sites and thereby favoring a pro-osteoclastic microenvironment. This suggests that bindarit may be an effective treatment for alphavirus-induced bone loss and arthritis in humans.

14 April 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
WCWeiqiang Chen
Weiqiang Chen
SFSuan-Sin Foo
Suan-Sin Foo
NRNestor E. Rulli
Nestor E. Rulli
Adam TaylorAdam Taylor
Adam Taylor
KSKuo-Ching Sheng
Kuo-Ching Sheng
SMSuresh Mahalingam
Suresh Mahalingam
Significance: Persistent polyarthritis, which occurs in 30–40% of alphavirus-infected patients, has been proposed to be caused by proinflammatory mediators such as IL-6. In the present study we investigated the susceptibility and response of primary human osteoblasts to Ross River virus (RRV) infection and determined whether infection could result in bone pathology. RRV infection of osteoblasts resulted in increased receptor activator of nuclear factor-kappaB ligand (RANKL) but decreased osteoprotegerin (OPG). We are the first to report that alphavirus infection results in bone loss in an established RRV murine model and that this bone loss is prevented by IL-6 inhibition. These findings reveal that RRV can disrupt bone homeostasis and that osteoblasts play an important role in alphavirus-induced arthritis by regulating IL-6 and contribute to bone loss by disrupting the RANKL/OPG balance.

25 May 2012 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
MNM. Noret
M. Noret
Lara HerreroLara Herrero
Lara Herrero
NRN. Rulli
N. Rulli
MRM. Rolph
M. Rolph
PSP. N. Smith
P. N. Smith
SMSuresh Mahalingam
Suresh Mahalingam